Reneo Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference
Reneo Pharmaceuticals (NASDAQ: RPHM) announced it will present at the Jefferies Virtual Healthcare Conference from June 1-4, 2021.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Reneo Pharmaceuticals (NASDAQ: RPHM) announced it will present at the Jefferies Virtual Healthcare Conference from June 1-4, 2021. The presentation, scheduled for June 1 at 1:00 PM ET, will be in a fireside chat format. Reneo focuses on therapies for rare genetic mitochondrial diseases, developing REN001, which aims to enhance ATP production and mitochondrial function. This therapy shows promise in increasing gene transcription related to metabolism and fatty acid oxidation.
Details
News Market Reaction – RPHM
The recorded move for RPHM in the trading session of this news was +5.62%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, May 19, 2021 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare, genetic, mitochondrial diseases, today announced that it will present and participate in one-on-one investor meetings at the upcoming Jefferies Virtual Healthcare Conference taking place June 1-4, 2021.
Presentation details can be found below.
| Date: | Tuesday, June 1, 2021 |
| Time: | 1:00 PM ET |
| Presentation Format: | Fireside chat |
About Reneo Pharmaceuticals
Reneo is a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP). Reneo is developing REN001 to modulate genes critical to metabolism and generation of ATP, which is the primary source of energy for cellular processes. REN001 has been shown to increase transcription of genes involved in mitochondrial function and increase fatty acid oxidation, and may increase production of new mitochondria.
Contacts:
Joyce Allaire
Managing Director
LifeSci Advisors, LLC
jallaire@lifesciadvisors.com
Vinny Jindal
Chief Financial Officer
Reneo Pharmaceuticals, Inc.
investors@reneopharma.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.